Hybrid Sirolimus-eluting Versus Everolimus-eluting Stents for Total Coronary Occlusions
NCT01516723
Arterial Occlusive Diseases, Arteriosclerosis
Antwerp, Antwerpen, Belgium
View Trial DetailsNCT Number: NCT02073331
The objective of the study is to actively gather additional information on the use of CorMatrix ECM for pericardial reconstruction.
Looking for future studies?
Notify MeAll sexes
Observational
Cario-Thoracic Surgeons, P.C., Birmingham, Alabama, United States
Up to 100 clinical sites will enroll subjects who have received CorMatrix ECM for pericardial reconstruction.
The following clinical data will be collected at a single post-operative visit:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Post-op visit, after an average of 30 days
Data will be collected at the initial post-operative visit. This is a single visit study.
Elutia Inc.
Industry
A Post Market Observational Study to Obtain Additional Information on the Use of CorMatrix ECM for Pericardial Reconstruction
Acronym: RECON
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01516723
Arterial Occlusive Diseases, Arteriosclerosis
Antwerp, Antwerpen, Belgium
View Trial DetailsNCT03253692
Arterial Occlusive Diseases, Arteriosclerosis
Lexington, Kentucky, United States
View Trial DetailsNCT03188705
Arterial Occlusive Diseases, Arteriosclerosis
Lancaster, Pennsylvania, United States
View Trial DetailsNCT02579655
Brain Diseases, Cardiovascular Diseases
Calgary, Alberta, Canada
View Trial Details